Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Rise of Mid-Sized Pharma
2.
Contract Research Annual Review 2008
3.
Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
4.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
5.
Monoclonal Antibodies Report: 2008 Update
6.
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players
7.
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
8.
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
9.
Drug Repositioning Strategies - Serendipity by design
10.
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Immunogenicity to Biologics Implications of reactions against biotech drugs
3.
Outsourcing in Drug Discovery, 3rd Edition
4.
American Hospital Register
5.
Professional Designation in Biopharmaceutical Technology - 3 Course Curriculum
6.
Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics
Drug Delivery Markets Vol IV Transdermal
New biological treatments are being developed at a record place, but their potential could be compromised by significant obstacles to delivery of these drugs into the body. Pharmaceutical delivery is now nearly as important as product. New systems are being developed, and Kalorama's Drug Delivery Markets Series covers these new systems.
The fourth volume of this series, Kalorama's Drug Delivery Markets, Vol. IV: Transdermal and Transmucosal Drug Delivery is a complete overview of a delivery mechansim that offers some advantages: low pain, infection risk, fewer side effects and polonged delivery over time.
Transdermal delivery has the advantage of being able deliver drugs over a long period of time, deliver a substantial amount and do so in a way that causes no pain or discomfort to the patient.
Nicotine patches have lead the growth in this delivery area, but new biological formulations will lead to continued growth.
Kalorama's Drug Delivery Series, Volume 4, Transdermal/Transmucosal Delivery covers the entire market of drugs delivered through the skin or muocus membrane. The transdermal/transmucosal drug delivery market is expected to grow steadily with biotechnology drugs that require novel delivery technologies leading this growth. The volume features
Complete Round-Up of Key Companies
Current Market Size for transdermal and transmucosal segments, as well as the pharmaceutical and technology-only segments
Forecasts to 2011 for Strategic Business Planning
Market coverage includes both the pharmaceutical products that utilize the drug delivery technology. The second section encompasses drug delivery technology and the revenues earned from licensing that technology. Because drug delivery technology is an integral part of sales of pharmaceuticals and drug delivery technology cannot exist without pharmaceuticals, revenues have been reported that include pharmaceutical sales for products utilizing that technology.
This market is expected to increase substantially within the forecast period. Additionally, a growing focus on ease of delivery to assist in patient compliance could help drive demand for both transdermal and transmucosal delivery systems.
Apr 1, 2007
118 Pages
PDF Format
Table of Contents
Price: $2,495.00 / GBP1,247.50
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.